SmithKline Beecham Clinical Laboratories, 506 E. State Parkway, Schaumburg, IL 60173, 708–885–2010; (name changed: formerly International Toxicology Laboratories)
SmithKline Beecham Clinical Laboratories, 11636 Administration Drive, St. Louis, MO 63146, 314–567–3905
SmithKline Beecham Clinical Laboratories, 400 Egypt Road, Norristown, PA 19403, 800–523–5447; (name changed: formerly SmithKline Bio-Science Laboratories)
SmithKline Beecham Clinical Laboratories, 8000 Sovereign Row, Dallas, TX 75247, 214–638–1301; (name changed: formerly SmithKline Bio-Science Laboratories)
South Bend Medical Foundation, Inc., 530 North Lafayette Boulevard, South Bend, IN 46601, 219–234–4176
Southgate Medical Laboratory, Inc., 21100 Southgate Park Boulevard, 2nd Floor, Maple Heights, OH 44137, 800–338–0166 outside OH/800–362–8913 inside OH
St. Anthony Hospital (Toxicology Laboratory), P.O. Box 205, 1000 North Lee Street, Oklahoma City, OK 73102, 405–272–7052
St. Louis University Forensic Toxicology Laboratory, 1205 Carr Lane, St. Louis, MO 63104, 314–577–8628
Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 314–882–1273
Toxicology Testing Service, Inc., 5426 N.W. 79th Avenue, Miami, FL 33166, 305–593–2260

Charles R. Schuster,

Director, National Institute on Drug Abuse.

[FR Doc. 91–26357 Filed 11–5–91; 8:45 am]

BILLING CODE 4160–20–M

Food and Drug Administration

[Docket No. 91N–0444]

Animal Drug Export; IVOMEC® Premix (Ivermectin) for Swine

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Merck Sharp & Dohme Research Laboratories has filed an application requesting approval for export of the animal drug IVOMEC® Premix (ivermectin) for Swine to the Netherlands to be repackaged and re-exported to the United Kingdom for sale in Ireland.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 1–23, 12420 Parklawn Drive, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of food animal drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person below.

FOR FURTHER INFORMATION CONTACT: Benjamin A. Puyot, Center for Veterinary Medicine (HFV–130), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–295–8646.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Merck Sharp & Dohme Research Laboratories, Division of Merck & Co., Inc., Rahway, NJ 07065, has filed an application requesting approval for export of the animal drug IVOMEC® Premix (ivermectin) for Swine to the Netherlands to be repackaged and re-exported to the United Kingdom for sale in Ireland. The product is intended for use in swine, feed for the treatment and control of swine parasites. The application was received and filed in the Center for Veterinary Medicine on October 10, 1991, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by November 18, 1991, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.44).

Dated: October 30, 1991.

Robert C. Livingston,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 91–26798 Filed 11–5–91; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 91N–0443]

Animal Drug Export; IVOMEC® Premix (Ivermectin) for Swine

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Merck Sharp & Dohme Research Laboratories has filed an application requesting approval for export of the animal drug IVOMEC® Premix (ivermectin) for Swine to the Netherlands to be repackaged and re-exported to the United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 1–23, 12420 Parklawn Drive, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of food animal drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person below.

FOR FURTHER INFORMATION CONTACT: Benjamin A. Puyot, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20846, 301–295–8646.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B)

have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Merck Sharp & Dohme Reseach Laboratories, Division of Merck & Co., Inc., Rahway, NJ 07065, has filed an application requesting approval for export of the animal drug IVOMEC® Premix (ivermectin) to the Netherlands to be repackaged and re-exported to the United Kingdom. The product is intended for use in swine feed for the treatment and control of swine parasites. The application was received and filed in the Center for Veterinary Medicine on October 10, 1991, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this documents. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by November 18, 1991, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.44).

Dated: October 30, 1991.

Robert C. Livingston,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 91-26799 Filed 11-5-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91F-0390]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of C_7-C_9 branched alkyl 3,5-di-*tert*-butyl-4-hydroxyhydrocinnamate as an antioxidant in lubricants that have incidental food contact.

FOR FURTHER INFORMATION CONTACT: Mitchell Cheeseman, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4290) has been filed by Ciba-Geigy Corp., Seven Skyline Dr., Hawthorne, NY 10532-2188. The petition proposes to amend § 178.3570 Lubricants with incidental food contact (21 CFR 178.3570) to provide for the safe use of C_7-C_9-branched alkyl 3,5-di-*tert*-butyl-4-hydroxyhydrocinnamate as an antioxidant for use in lubricants that have incidental contact with food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: October 24, 1991.

Douglas L. Archer,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-26800 Filed 11-5-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91F-0392]

Phoenix Medical Technology, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Phoenix Medical Technology, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 2,4,4'-trichloro-2-hydroxydiphenyl ether as an antimicrobial agent in the manufacture of polyvinyl chloride gloves for food-contact use.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (Sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4273) has been filed by Phoenix Medical Technology, Inc., P.O. Box 346, Andrews, SC 29510. The petition proposes to amend the food additive regulations to provide for the safe use of 2,4,4'-trichloro-2-hydroxydiphenyl ether as an antimicrobial agent in the manufacture of polyvinyl chloride gloves for food-contact use.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: October 24, 1991.

Douglas L. Archer,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-26801 Filed 11-6-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91F-0389]

Quantum Chemical Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Quantum Chemical Corp. has filed a petition proposing that the food additive regulations be amended to provide for an alternate method of determining the maximum extractable fraction of the polyolefins in *n*-hexane.

FOR FURTHER INFORMATION CONTACT: Daniel N. Harrison, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4291) has been filed by Quantum Chemical Corp., USI Division, 8805 North Tabler Rd., Morris, IL 60450. The petition proposes to amend the food additive regulations in § 177.1520 *Olefin polymers* (21 CFR 177.1520) to provide for an alternate method of determining the maximum extractable fraction of the polyolefins in *n*-hexane.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: October 24, 1991.

Douglas L. Archer,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-26802 Filed 11-5-91; 8:45 am]

BILLING CODE 4160-01-M

Health Resources and Services Administration

Filing of Annual Report of Federal Advisory Committee

Notice is hereby given that pursuant to section 13 of Public Law 92-463, the Annual Report for the following Health Resources and Service Administration's Federal Advisory Committee has been filed with the Library of Congress:

HRSA AIDS Advisory Committee

Copies are available to the public for inspection at the Library of Congress Newspaper and Current Periodical Reading Room, Room 1026, Thomas Jefferson Building, Second Street and Independence Avenue SE., Washington, DC, or weekdays between 9:00 a.m. and 4:30 p.m. at the Department of Health and Human Services, Department Library, HHS North Building, room G-619, 330 Independence Avenue SW., Washington, DC, telephone (202) 619-0791. Copies may be obtained from: Dr. Samuel C. Matheny, M.D., M.P.H., Executive Secretary, HRSA AIDS Advisory Committee, Room 14A-21, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443-4588.

Date: November 1, 1991.

Jackie E. Baum,

Advisory Committee Management Officer, HRSA.

[FR Doc. 91-26803 Filed 11-5-91; 8:45 am]

BILLING CODE 4160-15-M

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Meeting, National Diabetes Advisory Board

Pursuant to Public Law 92-463, notice is hereby given of the National Diabetes Advisory Board's meeting date which will be December 9-10, 1991. The Board will meet at the Crystal City Marriott in Arlington, Virginia. On December 9, the Board will sponsor a workshop on Obesity and Diabetes from approximately 8:30 a.m. to 4:30 p.m. On December 10, the Board will meet to discuss the 1992 Annual Report and future activities of the Board from 8 a.m. until approximately 3:30 p.m. Although the entire meeting will be open to the public, attendance will be limited to space available.

For any further information, please contact Mr. Raymond M. Kuehne, Executive Director, National Diabetes Advisory Board, 1801 Rockville Pike, Suite 500, Rockville, Maryland 20852, (301) 496-6045. His office will provide, for example, a membership roster of the Board and an agenda and summaries of the actual meetings.

Dated: November 1, 1991.

Raymond Bahor,

Acting Committee Management Officer, NIH.

[FR Doc. 91-26791 Filed 11-5-91; 8:45 am]

BILLING CODE 4140-01-M

National Institute of General Medical Sciences; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Minority Biomedical Research Support Review Subcommittee, National Institute of General Medical Sciences, November 14-15, 1991, Building 31C, Conference 9, National Institutes of Health which was published in the **Federal Register** on October 21, (56 FR 52554).

This committee was to have convened for 8:30 a.m. on November 14 and 15, but has been changed to 8:30 a.m. on December 9 and 10.

The committee was scheduled to meet in Building 31C, Conference Room 9, National Institutes of Health, but will now meet at the Holiday Inn, 5520 Wisconsin Avenue, Chevy Chase, Maryland.

Dated: November 1, 1991.

Raymond Bahor,

Acting Committee Management Officer, NIH.

[FR Doc. 91-26792 Filed 11-5-91; 8:45 am]

BILLING CODE 4140-01-M

National Institute of General Medical Sciences; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Cellular and Molecular Basis of Disease Review Committee, National Institute of General Medical Sciences, which was published in the **Federal Register** on October 21, (56 FR 52554).

This Committee was scheduled to meet at the Hyatt Regency Hotel, One Bethesda Metro Center, Bethesda, Maryland, but will not meet in Building 31C, Conference Room 9, National Institutes of Health, Bethesda, Maryland.

Dated: November 1, 1991.

Raymond Bahor,

Acting Committee Management Officer, NIH.

[FR Doc. 91-26793 Filed 11-5-91; 8:45 am]

BILLING CODE 4140-01-M

National Institute of General Medical Sciences; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Minority Access to Research Careers Review Subcommittee, National Institute of General Medical Sciences, which was published in the **Federal Register** on October 21, (56 FR 52554).

This Committee was scheduled to meet at the Holiday Inn, 8120 Wisconsin Avenue, Bethesda, Maryland, but will now meet at the Holiday Inn, 5520 Wisconsin Avenue, Chevy Chase, Maryland.

Dated: November 1, 1991.

Raymond Bahor,

Acting Committee Management Officer, NIH.

[FR Doc. 91-26794 Filed 11-5-91; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Public and Indian Housing

[Docket No. N-91-3237; FR-3013-N-03]

Funding Awards Under the Moderate Rehabilitation Program for Single Room Occupancy Dwellings for Homeless Individuals

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Announcement of funding awards.

SUMMARY: Under section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this announcement notifies the public of funding decisions made by the Department in a competition for rent assistance funds for Single Room Occupancy (SRO) Dwellings for Homeless Individuals. This announcement contains the names of